EGFR and non-small cell lung carcinoma: Currently, the use of osimertinib in combination with chemotherapy is being investigated as first-line therapy in EGFR-mutant NSCLC in the phase 3 FLAURA2 trial (NCT04035486) and in patients with detectable EGFR mutations in ctDNA in two phase 2 studies (NCT04410796, NCT05281406).